Accès gratuit
Volume 25, Numéro 2, Mars 2016
Page(s) 155 - 167
Section Mise Au Point / Update
Publié en ligne 1 février 2016
  • Thygesen K, Alpert JS, Jaffe AS, et al (2012) Third universal definition of myocardial infarction. Eur Heart J 33:2551–67 [CrossRef] [PubMed] [Google Scholar]
  • Meadows TA, Bhatt DL (2007) Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100:1261–75 [CrossRef] [PubMed] [Google Scholar]
  • Authors/Task Force Members, Roffi M, Patrono C, et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315 [CrossRef] [PubMed] [Google Scholar]
  • Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA (2014) Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circulation research 114:1929–43 [CrossRef] [PubMed] [Google Scholar]
  • Huber K, Bates ER, Valgimigli M, et al (2014) Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? Am Heart J 168:611–21 [CrossRef] [PubMed] [Google Scholar]
  • Patrono C, Andreotti F, Arnesen H, et al (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 32:2922–32 [CrossRef] [PubMed] [Google Scholar]
  • Authors/Task Force Members, Windecker S, Kolh P, et al (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–619 [CrossRef] [PubMed] [Google Scholar]
  • Andell P, James SK, Cannon CP, et al (2015) Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc [in press] [Google Scholar]
  • Investigators CO, Mehta SR, Bassand JP, et al (2010) Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. New Engl J Med 363:930–42 [CrossRef] [Google Scholar]
  • Antithrombotic Trialists Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324:71–86 [CrossRef] [PubMed] [Google Scholar]
  • Linden MD, Tran H, Woods R, Tonkin A (2012) High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 38:200–12 [CrossRef] [PubMed] [Google Scholar]
  • Silberman S, Neukirch-Stoop C, Steg PG (2005) Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 95:509–10 [CrossRef] [PubMed] [Google Scholar]
  • Wong JT, Nagy CS, Krinzman SJ, et al (2000) Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 105:997–1001 [CrossRef] [PubMed] [Google Scholar]
  • Schiano P, Steg PG, Barbou F, Monsegu J (2012) A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. Eur Heart J Acute Cardiovasc Care 1:75–8 [PubMed] [Google Scholar]
  • Dewilde WJ, Oirbans T, Verheugt FW, et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107–15 [CrossRef] [PubMed] [Google Scholar]
  • Mega JL, Braunwald E, Wiviott SD, et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. New Engl J Med 366:9–19 [CrossRef] [PubMed] [Google Scholar]
  • Task Force on the management of STseamiotESoC, Steg PG, James SK, et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–619 [CrossRef] [PubMed] [Google Scholar]
  • Steblovnik K, Blinc A, Bozic-Mijovski M, et al (2015) Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention 10:1418–24 [CrossRef] [PubMed] [Google Scholar]
  • Ibrahim K, Christoph M, Schmeinck S, et al (2014) High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 85:649–56 [CrossRef] [PubMed] [Google Scholar]
  • Parodi G, Valenti R, Bellandi B, et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61:1601–6 [CrossRef] [PubMed] [Google Scholar]
  • Yusuf S, Zhao F, Mehta SR, et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 345:494–502 [CrossRef] [PubMed] [Google Scholar]
  • Simon T, Verstuyft C, Mary-Krause M, et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. New Engl J Med 360:363–75 [CrossRef] [Google Scholar]
  • Collet JP, Hulot JS, Pena A, et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–17 [CrossRef] [PubMed] [Google Scholar]
  • Price MJ, Berger PB, Teirstein PS, et al (2011) Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–105 [CrossRef] [PubMed] [Google Scholar]
  • Collet JP, Cuisset T, Range G, et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. New Engl J Med 367:2100–9 [CrossRef] [Google Scholar]
  • Agewall S, Cattaneo M, Collet JP, et al (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 34:1708–13, 13a–13b [CrossRef] [PubMed] [Google Scholar]
  • Wiviott SD, Antman EM, Braunwald E (2010) Prasugrel. Circulation 122:394–403 [CrossRef] [PubMed] [Google Scholar]
  • Wiviott SD, Braunwald E, McCabe CH, et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 357:2001–15 [Google Scholar]
  • Montalescot G, Wiviott SD, Braunwald E, et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723–31 [CrossRef] [PubMed] [Google Scholar]
  • Wiviott SD, Braunwald E, Angiolillo DJ, et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118:1626–36 [CrossRef] [PubMed] [Google Scholar]
  • Wallentin L, Becker RC, Budaj A, et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 361:1045–57 [Google Scholar]
  • Held C, Asenblad N, Bassand JP, et al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57:672–84 [CrossRef] [PubMed] [Google Scholar]
  • Storey RF, Becker RC, Harrington RA, et al (2011) Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 32:2945–53 [CrossRef] [PubMed] [Google Scholar]
  • Steg PG, Bhatt DL, Hamm CW, et al (2013) Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382:1981–92 [CrossRef] [PubMed] [Google Scholar]
  • Montalescot G, Bolognese L, Dudek D, et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. New Engl J Med 369:999–1010 [Google Scholar]
  • Montalescot G, Collet JP, Ecollan P, et al (2014) Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol 64:2563–71 [CrossRef] [PubMed] [Google Scholar]
  • Donataccio MP, Puymirat E, Vassanelli C, et al (2014) Presentation and revascularization patterns of patients admitted for acute coronary syndromes in France between 2004 and 2008 (from the National Observational Study of Diagnostic and Interventional Cardiac Catheterization [ONACI]). Am J Cardiol 113:243–8 [CrossRef] [PubMed] [Google Scholar]
  • Collet JP, Silvain J, Bellemain-Appaix A, Montalescot G (2014) Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation 130:1904–14 [CrossRef] [PubMed] [Google Scholar]
  • Alexopoulos D, Bhatt DL, Hamm CW, et al (2015) Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J 170:3–12 [CrossRef] [PubMed] [Google Scholar]
  • Montalescot G, van 't Hof AW, Lapostolle F, et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. New Engl J Med 371:1016–27 [Google Scholar]
  • Mauri L, Kereiakes DJ, Yeh RW, et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. New Engl J Med 371:2155–66 [CrossRef] [Google Scholar]
  • Palmerini T, Benedetto U, Bacchi-Reggiani L, et al (2015) Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385:2371–82 [CrossRef] [PubMed] [Google Scholar]
  • Elmariah S, Mauri L, Doros G, et al (2015) Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 385:792–8 [CrossRef] [PubMed] [Google Scholar]
  • Navarese EP, Andreotti F, Schulze V, et al (2015) Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 350:h1618 [CrossRef] [PubMed] [Google Scholar]
  • Fifth Organization to Assess Strategies in Acute Ischemic Syndromes I, Yusuf S, Mehta SR, et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. New Engl J Med 354:1464–76 [CrossRef] [Google Scholar]
  • Group FO-T, Steg PG, Jolly SS, et al (2010) Low-dose vs. standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 304:1339–49 [CrossRef] [PubMed] [Google Scholar]
  • Montalescot G, Zeymer U, Silvain J, et al (2011) Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the International randomised open-label ATOLL trial. Lancet 378:693–703 [CrossRef] [PubMed] [Google Scholar]
  • American College of Emergency P, Society for Cardiovascular A, Interventions, O'Gara PT, et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:e78–e140 [CrossRef] [PubMed] [Google Scholar]
  • Stone GW, McLaurin BT, Cox DA, et al (2006) Bivalirudin for patients with acute coronary syndromes. New Engl J Med 355:2203–16 [CrossRef] [Google Scholar]
  • Stone GW, Witzenbichler B, Guagliumi G, et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. New Engl J Med 358:2218–30 [CrossRef] [Google Scholar]
  • Steg PG, van 't Hof A, Hamm CW, et al (2013) Bivalirudin started during emergency transport for primary PCI. New Engl J Med 369:2207–17 [CrossRef] [Google Scholar]
  • Shahzad A, Kemp I, Mars C, et al (2014) Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 384:1849–58 [CrossRef] [PubMed] [Google Scholar]
  • Valgimigli M, Frigoli E, Leonardi S, et al (2015) Bivalirudin or unfractionated heparin in acute coronary syndromes. New Engl J Med 373:997–1009 [CrossRef] [Google Scholar]
  • Greinacher A (2015) Clinical practice. Heparin-induced thrombocytopenia. New Engl J Med 373:252–61 [CrossRef] [Google Scholar]
  • Steg PG, Bonnefoy E, Chabaud S, et al (2003) Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 108:2851–6 [CrossRef] [PubMed] [Google Scholar]
  • Alexander JH, Lopes RD, James S, et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. New Engl J Med 365:699–708 [CrossRef] [Google Scholar]
  • Hansen ML, Sorensen R, Clausen MT, et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433–41 [CrossRef] [PubMed] [Google Scholar]
  • Lip GY, Windecker S, Huber K, et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35:3155–79 [CrossRef] [PubMed] [Google Scholar]
  • European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–429 [CrossRef] [PubMed] [Google Scholar]
  • Stefanini GG, Holmes DR Jr (2013) Drug-eluting coronary-artery stents. New Engl J Med 368:254–65 [CrossRef] [Google Scholar]
  • Valgimigli M, Patialiakas A, Thury A, et al (2015) Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 65:805–15 [CrossRef] [PubMed] [Google Scholar]
  • Pisters R, Lane DA, Nieuwlaat R, et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–100 [CrossRef] [PubMed] [Google Scholar]
  • Fiedler KA, Maeng M, Mehilli J, et al (2015) Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol 65:1619–29 [CrossRef] [PubMed] [Google Scholar]
  • Gibson CM, Mehran R, Bode C, et al (2015) An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 169:472–8 e5 [CrossRef] [PubMed] [Google Scholar]
  • Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr (2009) Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 53:2019–27 [CrossRef] [PubMed] [Google Scholar]
  • Subherwal S, Bach RG, Chen AY, et al (2009) Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 119:1873–82 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.